Navigation Links
Bavarian Nordic A/S - Half Year Interim Report 2009
Date:8/28/2009

the 2009 Genitourinary Cancers Symposium in Orlando, Florida.

The data, collected from three different studies confirm the excellent safety and efficacy results previously reported, and they support the further investigation in patients suffering from advanced prostate cancer. Also, the data indicate that PROSTVAC(TM) can be used in earlier disease settings and thus in a larger patient population.

In May 2009 detailed PROSTVAC(TM) data were presented at the 2009 ASCO Annual Meeting in Orlando, Florida. The presentation was made by Philip Kantoff MD, Professor of Medicine, Harvard Medical School, and the Dana-Farber Cancer Institute who is also the principal investigator of the study.

The more detailed analysis supports the headline data that were reported in October 2008. In the Phase 2 double-blind, prospective randomized placebo-controlled study of 125 patients with metastatic prostate cancer, patients in the PROSTVAC(TM) group had a significantly longer median overall survival by 8.5 months compared to the control group. The hazard ratio estimate for overall survival from the study is 0.56 (95% CI 0.37-0.85).

The statistical significance in the final data set is (p=0.006). These data were improved compared to the headline data presented in the fall in connection with the first announcement.

PROSTVAC(TM) immunotherapy was well tolerated, with some patients having injection site reactions (40-60%), and brief systemic symptoms of fatigue, fevers, and chills (10-30%) reported.

In July 2009, a review on PROSTVAC(TM) from key investigators from the National Cancer Institute (NCI) was published in the publication "Expert Opinion on Investigational Drugs", Volume 18, Issue 7 2009. This is the most comprehensive and updated review on PROSTVAC(TM) so far.

Quote from the article: "Preliminary clinical trials have indicated negligible toxicity, a
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Bavarian Nordic Publishes its Annual Results 2008
8. Bavarian Nordic Announces its Interim Report for the Period 1 January to 31 March 2009
9. The Court Supports Bavarian Nordics Decision to Start Patent Infringement Case Against Oxford BioMedica
10. Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)
11. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
(Date:1/14/2014)... Ontario , Jan. 14, 2014   Kinaxis ®, provider ... SCM ) and sales and operations planning ( S&OP ) ... Biomanufacturing Summit , which will be held at the ... the conference, join Kinaxis customer Elisabeth Kaszas , Director ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 During the 1600’s ... known as “The Doctor’s Plague.” In this time period, doctors ... This led, at times, to the death of vulnerable patients. ... don’t know that they may be unwittingly transmitting herpes viruses ...
(Date:1/14/2014)... Holloway America today announced an addition to ... (MTRs) for all pressure vessels and tank parts the ... important for equipment that must meet ASME, CE, PED, ... functionality that allows authorized users to quickly locate and ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense ... today reported financial and operational results for the third ... For the third quarter of 2009, PharmAthene recognized revenues ... same period of 2008. For the nine months ended ...
... ... on commercializing new patent portfolio into products and services , ... Laguna Niguel, CA (PRWEB) November 13, 2009 -- Applied Technology ... directors following the 2010 shareholders annual election of directors. , , ,Jay A. Shears ...
... Engineering and Applied Science at Northwestern University have developed, ... in atomic force microscopy (AFM), which images, measures, and ... researchers made a much more durable probe than the ... in AFM to gather information from a material, but ...
Cached Biology Technology:PharmAthene Reports Third Quarter 2009 Financial and Operational Results 2PharmAthene Reports Third Quarter 2009 Financial and Operational Results 3PharmAthene Reports Third Quarter 2009 Financial and Operational Results 4PharmAthene Reports Third Quarter 2009 Financial and Operational Results 5PharmAthene Reports Third Quarter 2009 Financial and Operational Results 6PharmAthene Reports Third Quarter 2009 Financial and Operational Results 7PharmAthene Reports Third Quarter 2009 Financial and Operational Results 8Applied Technology Holdings, Inc. Announces Board of Directors 2New nanocrystalline diamond probes overcome wear 2
(Date:4/22/2014)... of Montana,s Wildlife Biology Program, co-wrote a research paper published ... of Sciences on how streamwater chemistry varies across a ... Lowe and co-authors from ... the Cary Institute of Ecosystem Studies, the University of Connecticut ... water samples collected every 10 meters along 32 tributaries of ...
(Date:4/22/2014)... the fist-like club of a mantis shrimp, a team ... collaboration with University of Southern California and Purdue University, ... is more impact resistant and tougher than the standard ... club of this tiny crustacean, the more we realize ... every day," said David Kisailus, a Kavli Fellow of ...
(Date:4/22/2014)... have presented Beaumont Health System with prestigious, competitive ... both athletic and nonathletic injuries. , The ... $40,000 grant to fund stem cell-based research that ... a ruptured knee anterior cruciate ligament, or ACL. ... anterior cruciate ligament injury is the over-stretching or ...
Breaking Biology News(10 mins):New research focuses on streamwater chemistry, landscape variation 2Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3Beaumont awarded grants to study sports-related injury treatment, improve recovery 2
... AWRE ), a leading supplier of broadband technology and biometrics ... 30, 2011.   Revenue for the second quarter of ... million in the same quarter last year. The net loss for ... share. These results compared to a net loss of $148,000, or ...
... Clearbridge Accelerator announced today that it has received an ... in the Silicon Valley. Mr Draper, who is the ... (DFJ), is well known for making early-stage investments in ... Accelerator is a technology incubator that focuses on commercialising ...
... , BLOOMINGTON, Ind. -- A visiting researcher from Sweden in ... has led an international team in culturing, characterizing and formally ... been identified through DNA sequencing from environmental samples. ... Archaeorhizomyces , previously known as Soil Clone Group 1 (SCG1), ...
Cached Biology News:Aware, Inc. Reports Second Quarter 2011 Financial Results 2Aware, Inc. Reports Second Quarter 2011 Financial Results 3Aware, Inc. Reports Second Quarter 2011 Financial Results 4Aware, Inc. Reports Second Quarter 2011 Financial Results 5Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 2Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 3Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 4Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 5Singapore Technology Incubator Receives Investment from Silicon Valley "Super-Angel" 6Visiting researcher at IU leads international team in formal identification of new fungi class 2Visiting researcher at IU leads international team in formal identification of new fungi class 3